ZVSA earnings analysis
What we found in ZVSA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ZyVersa Therapeutics, Inc. reported a net loss of $1.8 million for Q1 2026, a 53.9% reduction from the $2.3 million loss in Q1 2025. Operating expenses fell significantly, with research and development costs dropping 77.6% to $58 thousand and general and administrative expenses decreasing 33.9% to $1.2 million. The company's cash position improved to $0.3 million, but remains critically low to fund ongoing operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Improvement
- Net losses narrowed to $1.8 million in Q1 2026 from $2.3 million in Q1 2025, reflecting a 53.9% reduction.
- Dramatic Drop in R&D Costs
- Research and development expenses decreased to $58 thousand, a 77.6% reduction from $259 thousand in the prior year.
- Lower Operating Expenses
- Total operating expenses fell to $1.3 million, down 39.2% from $2.1 million a year prior.
- Cash Position Stabilized
- ZyVersa's cash position improved to $0.3 million by March 31, 2026, from $0.1 million at the end of 2025.
- Decreased Cash Used in Operations
- Net cash used in operating activities dropped to $799 thousand from $1.772 million in the same quarter last year.
- Financing Cash Inflows
- Net cash from financing activities provided $1 million in Q1 2026, a decrease from $1.9 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Working Capital Deficiency
- As of March 31, 2026, ZyVersa reported a working capital deficiency of $(14.125) million versus $(12.387) million a year prior.
- Critical Need for Additional Financing
- The company requires ongoing financing to support operations, stating additional capital will be needed imminently.
- Going Concern Risk
- Management expresses substantial doubt about the ability to continue as a going concern for the next 12 months, pending further capital.
What they said about what is next.
No numerical guidance provided; management continues to anticipate significant operating losses.
The filing reads better than the one before it.
What came before.
- 10-K · March 31, 2026
- ZyVersa is a clinical‑stage biopharma focused on renal candidate VAR 200 and inflammasome inhibitor IC 100 but has no commercial products or revenue. In 2025 the company recorded a net loss of $24.95 million (including…
- 10-Q · May 12, 2025
- ZyVersa reported a net loss of $2,256,930 for Q1 2025 (EPS $(0.73)) and had cash of $1,611,532 as of March 31, 2025. Operating expenses declined year-over-year (R&D $258,876; G&A $1,885,695) and cash used in operations…
- 10-Q · August 9, 2024
- ZyVersa reported a materially smaller GAAP loss in Q2 2024 as impairments recorded in the prior-year quarter did not recur; net loss for Q2 2024 was $(2,763,743) versus $(78,513,093) in Q2 2023. Liquidity is the primary…
- 10-K · March 25, 2024
- ZyVersa is a clinical-stage biopharmaceutical company (post-December 12, 2022 business combination) developing lead candidates VAR 200 and IC 100 and has not generated any product revenue. For the year ended December…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZVSA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever